“…Further, low plasma protein binding (20%) and very low t 1/2 (1-1.5 hours) and lack of stability in gastric acidic pH calls for the design of novel pharmaceutical formulations (Wilson, Lee, Mukherji, 2002). Several formulation approaches have been explored to develop sustained release dosage forms of AMT to address the above-mentioned problems (Bonev, Hopper, Parisot, 2008;Hilton, Deasy, 1992;Patel, Amiji, 1996;Risbud, Hardikar, Bhat, 2000). The novel time-dependent release bilayer tablets comprised of a delayed release layer (i.e., Eudragit-L100 D55 as pH dependent enteric polymer which releases the drug after specific lag-time), and a sustained release layer (i.e., HPMCK4M and HPMCK15).…”